Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Atopic Dermatitis: Update Bulletin #3 [June 2018]

Product Code:
Publication Date:
June 2018

This edition presents key opinion leader (KOL) views on recent developments in the Atopic Dermatitis (AD) market. Topics covered include; AnaptysBio presenting updated data from a Phase IIa trial of the anti-interleukin (IL)-33 antibody ANB020 in patients with moderate-to-severe AD; Glenmark Pharmaceuticals presenting new Phase IIa data for its anti-OX40 monoclonal antibody (mAb) GBR 830; XBiotech announcing that the first patient had been treated in a Phase II study evaluating the human-derived anti-IL-1 alpha antibody MABp1 as a therapy for moderate-to-severe AD.

Business Questions:

• To what extent do the updated Phase IIa results confirm ANB020’s potential as an effective therapy for AD?
• Do KOLs think that targeting IL-33 constitutes a safe and effective approach for treating AD?
• How do KOLs think that ANB020 would be utilised within the treatment algorithm if it received marketing authorisation for AD?
• Are the new Phase IIa results adequate for assessing GBR 830’s potential as an AD therapy or will further study be required?
• Does OX40 receptor inhibition represent a safe and effective method for treating AD?
• Where do KOLs think that GBR 830 will be positioned within the treatment paradigm if it receives regulatory approval as an AD therapy?
• How effective is IL-1 alpha inhibition likely to be as a means to reduce the inflammation associated with AD?
• Do KOLs expect to see any adverse effects associated with the use of MABp1 as a therapy for AD?
• Is it possible to predict with any confidence what sort of role MABp1 will play in the treatment of AD or is it too early to draw any meaningful conclusions?


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved